TP53 and cancer: The first demonstration of CRISPR/Cas inhibiting HPV-related cancers was sgRNAs targeted to HPV16′s E6 and E7 proteins in the cervical cancer-derived SiHa cells, which increased p53 and it downstream factor, p21, resulting in reduced cell viability [27].